Skip to content
Search

Latest Stories

Higher risk of prostate cancer linked to weight gain before 30: Study

The study found that a weight gain of two stone between the ages of 17 and 29 heightens the risk of aggressive prostate cancer diagnosis by 13 per cent

Higher risk of prostate cancer linked to weight gain before 30: Study

A significant study has revealed that young men who experience a weight gain of two stone (28 pounds) before the age of 30 are at a considerably higher risk of prostate cancer-related mortality later in life.

Researchers from Sweden conducted a comprehensive investigation involving 258,000 men, monitoring them throughout their adult years. The study found a correlation between weight gain and an elevated likelihood of developing prostate cancer, particularly in its aggressive form.


Surprisingly, weight gain during the late teenage years and twenties was identified as the primary factor contributing to prostate cancer, despite the disease typically manifesting in men over the age of 50.

The study found that a weight gain of two stone between the ages of 17 and 29, which is equivalent to an annual increase of 2.2 pounds (1 kilogram), heightens the risk of aggressive prostate cancer diagnosis by 13 per cent.

Furthermore, it raises the probability of prostate cancer-related mortality by 27 per cent compared to men who maintain a stable weight.

Similarly, men who experience gradual weight gain throughout their lifetime, at an approximate rate of 1.1 pounds (0.5 kilograms) per year, face a similar increased risk.

The findings, which are currently awaiting peer review, originated from the Obesity and Disease Development Sweden study conducted between 1963 and 2014.

In this study, researchers meticulously analysed data from Swedish men who had their weight measured on a minimum of three occasions spanning from the ages of 17 to 60.

Dr Marisa da Silva, of the department of translational medicine at Lund University, said, “Knowing more about the factors that cause prostate cancer is key to preventing it."

She also stated that it remains unclear whether it is the weight gain itself or the prolonged period of being overweight that primarily contributes to the observed association.

Previous studies have suggested a link between elevated levels of insulin-like growth factor-1 (IGF-1), a hormone involved in cell growth and development, and an increased risk of prostate cancer.

She further explained that individuals with obesity tend to have higher levels of this hormone, and a rapid increase in weight may further elevate these levels, potentially fueling the development of the cancer.

The comprehensive study involved a vast cohort of 258,477 men. These participants were closely monitored for an average duration of 43 years.

It was found that throughout the study period, 23,348 men received a diagnosis of prostate cancer, typically at an average age of 70. Tragically, 4,790 men succumbed to the disease.

Simon Grieveson, the assistant director of research at Prostate Cancer UK, commented on the study's findings, stating, "Several studies have indicated a possible correlation between being overweight and aggressive prostate cancer, and this study builds on those by suggesting that weight gain earlier in life is associated with an increased risk of dying from the disease."

Grieveson emphasised the need for further research to comprehensively understand the biological connection between obesity and prostate cancer.

He highlighted the importance of utilising this knowledge to improve outcomes for men affected by the disease. Prostate Cancer UK is actively funding research in this area.

Grieveson also emphasised that maintaining a healthy weight can provide protection against various types of cancer, including prostate cancer. However, he emphasised that the disease can affect men of all weights, shapes, and sizes.

He said men over the age of 50, Black men, and those with a family history of prostate cancer are at the highest risk. Thus, Grieveson encouraged individuals in these groups to consult their doctors if they have any concerns.

In the UK, prostate cancer stands as the most prevalent cancer among men, with one in eight individuals receiving a diagnosis during their lifetime. The disease accounts for 52,000 cases and causes 12,000 deaths annually.

Prostate cancer primarily affects men who are 50 years of age and older, and the risk of developing the disease escalates as individuals age.

The most prevalent age range for prostate cancer diagnosis is between 70 and 74 years.

More For You

Prada 2026 sandals

Prada acknowledges Indian influence behind its Spring Summer 2026 men’s footwear

Instagram/prada/iStock

Prada finally acknowledges Kolhapuri chappals inspired 2026 sandals after Indian backlash over Milan show

Quick highlights:

• Prada confirms Indian roots behind 2026 ‘leather sandals’ after controversy
• Indian artisans and officials accused the brand of cultural appropriation
• The footwear resembles traditional Kolhapuri chappals with GI status
• Prada says designs are still in development and open to dialogue with India

Keep ReadingShow less
Anna Wintour

Wintour’s style of leadership earned her the nickname “Nuclear Wintour”

Getty Images

Anna Wintour steps down as editor of US Vogue after 37 years

Key points

  • Anna Wintour steps down as editor of US Vogue after 37 years
  • She will remain Vogue’s global editorial director and hold senior roles at Condé Nast
  • Wintour transformed US Vogue into a global fashion authority
  • The 75-year-old has received numerous honours, including the Presidential Medal of Freedom

End of an era at US Vogue

Anna Wintour has stepped down as the editor of US Vogue, bringing to a close a 37-year tenure that redefined the publication and saw her become one of the most influential figures in global fashion.

The announcement was made on Thursday (26 June) during a staff meeting in New York. Wintour, 75, will no longer oversee the day-to-day editorial operations of Vogue’s US edition. However, she will continue to serve as Vogue’s global editorial director and Condé Nast’s chief content officer, maintaining senior leadership roles across the company.

Keep ReadingShow less
Nadiya Hussain

She also reassured her followers that “exciting” new projects are on the way

Getty Images

“I won’t always be grateful” says Nadiya Hussain after BBC axes her cookery show

Key points

  • Nadiya Hussain confirms BBC will not renew her cookery series
  • Bake Off winner challenges expectations to remain “grateful”
  • She says hard work and talent, not luck, brought her success
  • Celebrities, including Annie Lennox and Fearne Cotton, show support

BBC ends decade-long collaboration with Bake Off star

Nadiya Hussain has spoken out after the BBC decided not to commission another cookery programme with her. The popular TV chef, who won The Great British Bake Off in 2015, shared her views on social media, stating that she “won’t always be grateful” and should not be expected to remain silent about career setbacks.

The decision ends a nearly 10-year working relationship between the broadcaster and Hussain, who has hosted several well-received cookery shows under the BBC banner. In her latest Instagram video, she addressed the public’s reaction and emphasised her right to expect more from her career.

Keep ReadingShow less
weight loss injections UK

The importance of vigilance as demand for these weight loss and diabetes drugs continues to grow

iStock

Hundreds report pancreas issues linked to weight loss injections as UK launches safety study

Key points

  • Almost 400 reports of acute pancreatitis linked to weight loss and diabetes jabs have been filed in the UK
  • Most cases involve popular GLP-1 drugs including Ozempic, Wegovy, and Mounjaro
  • Health officials are investigating possible genetic causes behind the side-effects
  • Patients hospitalised with pancreatitis encouraged to report symptoms via MHRA’s Yellow Card scheme
  • Adverse drug reactions cost the NHS an estimated £2.2bn annually

Health watchdog investigates spike in serious side-effects from GLP-1 drugs

UK health authorities have launched a study into the side effects of popular weight loss and diabetes drugs following a spike in reported cases of acute pancreatitis. Nearly 400 reports have been received via the Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, which monitors side effects and adverse reactions related to medicines and medical devices.

The medicines involved are GLP-1 receptor agonists – including semaglutide (marketed as Ozempic and Wegovy), liraglutide, and tirzepatide (branded as Mounjaro). The Yellow Card data shows that 181 of the cases involved tirzepatide alone.

Keep ReadingShow less
M&S launches strawberries

M&S’s latest offering taps into both tradition and innovation

The Wire

M&S launches strawberries and cream sandwich ahead of Wimbledon

Summary

  • M&S unveils limited edition strawberries and cream sandwich for £2.80
  • Inspired by Japanese 'sweet sandos', it features Red Diamond strawberries and whipped cream cheese
  • Available in stores now, found in the savoury sandwich aisle
  • Launch coincides with Wimbledon and British strawberry season
  • Wimbledon increases strawberries and cream price for first time in 15 years

New summer sandwich from M&S

Marks & Spencer has launched a limited edition M&S strawberry sandwich, combining classic British summer flavours with a Japanese twist. Priced at £2.80, the strawberries and cream sandwich is available in M&S stores now.

The dessert-style sandwich features M&S’s exclusive Red Diamond strawberries, whipped cream cheese, and sweetened bread. Despite its sweet contents, the product is found in the savoury sandwich section of M&S Food halls.

Keep ReadingShow less